Brain metastases (BM) are common in non-small cell lung cancer patients including in
molecularly selected populations, such as EGFR-mutant and ALK-rearranged tumors. They …

Brain metastases (BM) are severe incidents in patients with non–small‐cell lung cancer
(NSCLC). The controversial value of prophylactic cranial irradiation (PCI) in NSCLC in terms …

Background Lung cancer is the leading cause of cancer-related death worldwide. Numerous
studies have been performed to investigate the correlation between epidermal growth factor …

Simple Summary Precision cancer medicine depends on the characterization of tumor
samples, usually by a single-tumor biopsy, to administer an optimal therapeutic. However …

Patients with epidermal growth factor receptor (EGFR)-positive (EGFR+) non–small-cell lung
cancer (NSCLC) show improved response rates when treated with tyrosine kinase inhibitors …

Human non‑small cell lung cancer (NSCLC) is associated with an extremely poor prognosis
especially for the 40% of patients who develop brain metastasis, and few treatment …

Background. Patients with brain metastases (BM) from renal cell carcinoma (RCC) were
considered to experience a poor prognosis. However, there is little knowledge on the risk …

Background: Leptomeningeal disease (LMD) is a complication that results from solid tumor
metastasis. Prognosis is extremely poor. As therapeutic options for solid tumors improve, the …

Background The epidermal growth factor receptor (EGFR) mutation is a risk factor
associated with brain metastases (BMs) in patients with non‐small cell lung cancer …

Many noninvasive methods have been explored to determine the mutation status of the
epidermal growth factor receptor (EGFR) gene, which is important for individualized …